Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

142.62 USD +7.73 (+5.73%)
Official Closing Price Updated: 7:44 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ligand Pharm

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan
Accord allows Sermonix to globally develop and commercialize drug for treatment of advanced breast cancer 
From Marketwired News Releases
Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for... 
From Business Wire News Releases
Ligand Reports Fourth Quarter and Full Year 2016 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Christel Iffland, Ph.D. as a Vice President of Antibody Technologies. 
From Business Wire News Releases
Reminder: Ligand to Host Analyst Day on February 28th in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.m. to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in New York... 
From Business Wire News Releases
Ligand to Host Analyst Day on February 28th in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.m. to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in New York... 
From Business Wire News Releases
Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2016 financial results on February 23, 2017. Ligand’s CEO John Higgins, President and COO... 
From Business Wire News Releases
Lemelson Capital Management Announces 2016 Performance Results for The Amvona Fund, LP
Firm's flagship fund returns 84.97 percent net of all fees and expenses in 2016 
From PR Newswire
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017
Levi & Korsinsky reminds shareholders of Ligand Pharmaceuticals of commencement of a class action lawsuit. 
From Business Wire News Releases
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
From ACCESSWIRE
Deadline in Lawsuit for Investors in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced by Shareholders Foundation
The Shareholders Foundation, Inc. announces that a deadline is coming up on January 17, 2017 in the lawsuit that was filed for certain investors in NASDAQ: LGND shares over alleged Securities Laws... 
From GlobeNewswire News Releases
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
From ACCESSWIRE
LGND SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced on behalf of investors who purchased Ligand Pharmaceuticals Inc. 
From Business Wire News Releases
Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced a newly reconstituted Board of Directors and the implementation of a leadership succession plan. 
From GlobeNewswire News Releases
DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Ligand Pharmaceuti
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of... 
From Business Wire News Releases
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
From ACCESSWIRE
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
From ACCESSWIRE
LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important January 17 Deadline in Class Action Filed by Firm - LGND
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both dates... 
From GlobeNewswire News Releases
Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the Lead Plaintiff Deadline of January 17, 2017
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who... 
From Business Wire News Releases
LGND INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals... 
From PR Newswire
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
From ACCESSWIRE
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
From ACCESSWIRE
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”)... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017
Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Ligand Pharmaceuticals, Inc. who purchased shares between November 9, 2015 and November 14, 2016. 
From Business Wire News Releases
Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral... 
From Business Wire News Releases
Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ONO PHARMACEUTICAL CO., LTD. (TSE: 4528). Under the license, ONO will be able to use... 
From Business Wire News Releases
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
From ACCESSWIRE
Lantern Foundation Founder Urges Senate Committee to Commence Investigation into Ligand Pharmaceuticals
Abuse of Orphan Drug Act, Accounting and Ethical Violations Warrant Congressional and Regulatory Investigation, Organization's Founder Says 
From PR Newswire
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
From ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.